The Krannert Institute of Cardiology has one of the nations most robust heart failure and heart transplant programs. The nationally recognized Heart Failure Program is among the few cutting edge comprehensive multidisciplinary programs in the world.  It offers a comprehensive medical, surgical and mechanical approach to the management of patients with advanced heart failure.

The Heart Failure Program has one of the highest volume left ventricular assist device (LVAD) programs in the country.  LVADs or mechanical heart pumps are the latest technological advances in the surgical treatment of heart failure.  LVADs support the pumping action of the heart while the heart rests and recovers.  They can be used to transition and support people until they get a heart transplant or they can help end-stage heart failure patients have a better quality and quantity of life with independence and autonomy at home.  Their ability to restore near normal quality of life and to markedly improve survival while remaining at home has led many of our patients to tell us that they feel truly blessed to get a "second chance" to live life to the fullest.

The Krannert Institute's participation and pioneering role in cutting edge LVAD device trials has allowed our patients access to the latest, finest innovations in heart pump technology in the world.  Our high volumes and spectacular outcomes in LVAD therapy have earned us the distinction of being one of the premier pioneering institutes in cardiovascular medicine.  Furthermore, our team and support staff address our patients and their loved ones every medical and psychosocial needs, leading to one of the highest satisfaction rates within the country.  With the aid of our basic scientists and research teams, we are also actively investigating and diligently working on cutting edge research, such as stem cell and gene therapy, to better help patients with advanced heart failure.

Visit http://www.thoratec.com for further information about LVADs.